Zacks Research Comments on Fresenius Medical Care AG & Co. KGaA’s Q2 2023 Earnings (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) – Zacks Research decreased their Q2 2023 earnings per share estimates for Fresenius Medical Care AG & Co. KGaA in a report released on Tuesday, May 23rd. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings per share of $0.26 for the quarter, down from their prior estimate of $0.28. The consensus estimate for Fresenius Medical Care AG & Co. KGaA’s current full-year earnings is $1.15 per share. Zacks Research also issued estimates for Fresenius Medical Care AG & Co. KGaA’s Q3 2023 earnings at $0.28 EPS, FY2023 earnings at $1.14 EPS, FY2024 earnings at $1.46 EPS, Q1 2025 earnings at $0.32 EPS and FY2025 earnings at $1.66 EPS.

Several other research analysts have also commented on FMS. StockNews.com assumed coverage on Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, May 18th. They issued a “buy” rating for the company. HSBC downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “reduce” rating in a research note on Tuesday, March 7th. Sanford C. Bernstein started coverage on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, March 7th. They set a “market perform” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Finally, Truist Financial lifted their price target on Fresenius Medical Care AG & Co. KGaA from $22.00 to $24.00 and gave the stock a “hold” rating in a research note on Thursday, April 13th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of “Hold” and a consensus target price of $28.45.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $22.18 on Thursday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $12.78 and a fifty-two week high of $30.63. The business has a 50 day moving average price of $22.30 and a two-hundred day moving average price of $19.12. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 0.48. The firm has a market cap of $13.02 billion, a PE ratio of 20.92 and a beta of 1.01.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last issued its quarterly earnings data on Tuesday, February 21st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.22. Fresenius Medical Care AG & Co. KGaA had a return on equity of 5.44% and a net margin of 3.06%. The firm had revenue of $5.10 billion during the quarter, compared to analyst estimates of $4.85 billion.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors have recently made changes to their positions in FMS. Raymond James & Associates lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 35.6% during the 1st quarter. Raymond James & Associates now owns 28,440 shares of the company’s stock valued at $958,000 after buying an additional 7,470 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 13.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 9,490 shares of the company’s stock valued at $320,000 after buying an additional 1,089 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 17.4% during the 1st quarter. Bank of New York Mellon Corp now owns 28,037 shares of the company’s stock valued at $945,000 after buying an additional 4,162 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 15.0% during the 1st quarter. American Century Companies Inc. now owns 9,477 shares of the company’s stock valued at $319,000 after buying an additional 1,238 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 56.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 29,668 shares of the company’s stock valued at $1,000,000 after buying an additional 10,676 shares during the last quarter. 5.56% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 1st. Stockholders of record on Thursday, May 18th will be issued a dividend of $0.7086 per share. The ex-dividend date is Wednesday, May 17th. This represents a dividend yield of 2.1%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is 39.62%.

About Fresenius Medical Care AG & Co. KGaA

(Get Rating)

Fresenius Medical Care AG & Co KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management.